Immuneering Corp
For the period ended Jan 13, 2025. Filed Jan 13, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jan 13, 2025 · Filed Jan 13, 2025
Use the contents to explore the available documents and sections.
Contents
Recent Developments
On January 13, 2025, Immuneering Corporation (the "Company") announced updated interim response and safety data from the ongoing Phase 2a arm evaluating IMM-1-104 with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients, part of the Company's ongoing Phase 1/2a clinical trial of IMM-1-104 in patients with advanced RAS-mutant solid tumors.
The Company announced that, as of January 6, 2025, of the six evaluable patients in the ongoing Phase 2a arm evaluating IMM-1-104 with mFFX in first-line pancreatic cancer, three patients achieved a partial response (one unconfirmed) and three patients achieved stable disease, collectively representing an interim 50% (3/6) overall response rate (ORR), in each case as measured by RECIST. The three patients that achieved partial responses, and one of the patients that achieved stable disease, remained on treatment. The Company also announced that, as of January 6, 2025, IMM-1-104 in combination with mFFX was observed to be generally well tolerated.
On January 13, 2025, the Company also announced that it raised net proceeds of $13.7 million in January 2025, through utilization of the Company's at-the-market equity offering program.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.